Royal Bank of Canada’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13K | Sell |
1,515
-3,067
| -67% | -$27.6K | ﹤0.01% | 6079 |
|
|
2025
Q4 | $42K | Sell |
4,582
-5,109
| -53% | -$48.3K | ﹤0.01% | 5651 |
|
|
2025
Q3 | $93K | Sell |
9,691
-108,546
| -92% | -$1.09M | ﹤0.01% | 5548 |
|
|
2025
Q2 | $1.04M | Buy |
118,237
+116,602
| +7,132% | +$946K | ﹤0.01% | 3865 |
|
|
2025
Q1 | $12K | Sell |
1,635
-3,269
| -67% | -$26K | ﹤0.01% | 6112 |
|
|
2024
Q4 | $41K | Sell |
4,904
-522
| -10% | -$4.46K | ﹤0.01% | 5786 |
|
|
2024
Q3 | $39K | Buy |
5,426
+268
| +5% | +$1.82K | ﹤0.01% | 5818 |
|
|
2024
Q2 | $25K | Buy |
5,158
+3,141
| +156% | +$14.9K | ﹤0.01% | 5974 |
|
|
2024
Q1 | $12K | Sell |
2,017
-12,736
| -86% | -$78.3K | ﹤0.01% | 6143 |
|
|
2023
Q4 | $97K | Buy |
14,753
+6,853
| +87% | +$32.1K | ﹤0.01% | 5643 |
|
|
2023
Q3 | $39K | Buy |
7,900
+1,348
| +21% | +$6.73K | ﹤0.01% | 5913 |
|
|
2023
Q2 | $33K | Buy |
6,552
+5,365
| +452% | +$28.9K | ﹤0.01% | 5968 |
|
|
2023
Q1 | $7K | Sell |
1,187
-4,935
| -81% | -$26.1K | ﹤0.01% | 6469 |
|
|
2022
Q4 | $29K | Buy |
6,122
+1,892
| +45% | +$9.61K | ﹤0.01% | 6153 |
|
|
2022
Q3 | $26K | Sell |
4,230
-1,954
| -32% | -$11.1K | ﹤0.01% | 6044 |
|
|
2022
Q2 | $27K | Sell |
6,184
-4,695
| -43% | -$21.4K | ﹤0.01% | 5977 |
|
|
2022
Q1 | $55K | Sell |
10,879
-4,235
| -28% | -$26.9K | ﹤0.01% | 6025 |
|
|
2021
Q4 | $132K | Buy |
15,114
+5,801
| +62% | +$51.8K | ﹤0.01% | 5727 |
|
|
2021
Q3 | $86K | Buy |
9,313
+1,687
| +22% | +$17K | ﹤0.01% | 5817 |
|
|
2021
Q2 | $98K | Buy |
7,626
+1,878
| +33% | +$20.2K | ﹤0.01% | 5626 |
|
|
2021
Q1 | $53K | Buy |
+5,748
| New | +$50.2K | ﹤0.01% | 5845 |
|
|
2020
Q2 | – | Sell |
-5,973
| Closed | -$21K | – | 6954 |
|
|
2020
Q1 | $21K | Sell |
5,973
-23
| -0.4% | -$127 | ﹤0.01% | 5528 |
|
|
2019
Q4 | $36K | Buy |
5,996
+798
| +15% | +$6.34K | ﹤0.01% | 5606 |
|
|
2019
Q3 | $57K | Sell |
5,198
-2,207
| -30% | -$39.9K | ﹤0.01% | 5075 |
|
|
2019
Q2 | $207K | Buy |
7,405
+8
| +0.1% | +$201 | ﹤0.01% | 4465 |
|
|
2019
Q1 | $198K | Buy |
7,397
+4,560
| +161% | +$168K | ﹤0.01% | 4360 |
|
|
2018
Q4 | $80K | Buy |
2,837
+953
| +51% | +$38.6K | ﹤0.01% | 4846 |
|
|
2018
Q3 | $145K | Buy |
1,884
+189
| +11% | +$14.8K | ﹤0.01% | 4666 |
|
|
2018
Q2 | $176K | Buy |
1,695
+187
| +12% | +$18.3K | ﹤0.01% | 4488 |
|
|
2018
Q1 | $191K | Buy |
1,508
+1,431
| +1,858% | +$138K | ﹤0.01% | 4342 |
|
|
2017
Q4 | $5K | Buy |
77
+70
| +1,000% | +$4.22K | ﹤0.01% | 6079 |
|
|
2017
Q3 | $0 | Buy |
7
+1
| +17% | +$53 | ﹤0.01% | 7023 |
|
|
2017
Q2 | $0 | Hold |
6
| – | – | ﹤0.01% | 6802 |
|
|
2017
Q1 | $0 | Hold |
6
| – | – | ﹤0.01% | 6853 |
|
|
2016
Q4 | $0 | Sell |
6
-125
| -95% | -$7.67K | ﹤0.01% | 6809 |
|
|
2016
Q3 | $9K | Hold |
131
| – | – | ﹤0.01% | 5822 |
|
|
2016
Q2 | $8K | Buy |
131
+125
| +2,083% | +$20.6K | ﹤0.01% | 5818 |
|
|
2016
Q1 | $1K | Sell |
6
-652
| -99% | -$158K | ﹤0.01% | 6242 |
|
|
2015
Q4 | $209K | Buy |
658
+620
| +1,632% | +$168K | ﹤0.01% | 4486 |
|
|
2015
Q3 | $12K | Sell |
38
-6
| -14% | -$1.84K | ﹤0.01% | 5814 |
|
|
2015
Q2 | $13K | Buy |
+44
| New | +$9.6K | ﹤0.01% | 5945 |
|
Other funds holding ZVRA
WP
NCM
VCM
ACM
Royal Bank of Canada's ZVRA Position: Q1 2026 in Review
Royal Bank of Canada reduced its Zevra Therapeutics (ZVRA) stake by 67% in Q1 2026, selling an estimated $27.6K and leaving 1,515 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #6079.
Royal Bank of Canada first reported a position in ZVRA in Q2 2015 and has held it in 41 quarters since. The position peaked at $1.04M in Q2 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.
- Royal Bank of Canada held 1,515 shares of Zevra Therapeutics worth $13K as of Q1 2026.
- Royal Bank of Canada sold 3,067 Zevra Therapeutics shares in Q1 2026, an estimated $27.6K.
- Zevra Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6079 holding.
- Royal Bank of Canada first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 41 quarters since.
- Royal Bank of Canada's Zevra Therapeutics position peaked at $1.04M in Q2 2025.
- 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.